Tempus AI Inc. surged as a pivotal healthcare AI partnership fueled optimism, and stocks have been trading up by 14.41 percent.
Click Here for a Millionaire's POV on Trading TEM
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Q2 2026 saw TEM revenue jump 22% to $382.5M, alongside a move to positive net income and EBITDA.
- Strong oncology testing and rapid growth in Data and Applications support Tempus AI’s precision‑medicine and data‑licensing strategy.
- Tempus AI agreed to buy Personalis for $16.25 per share, valuing the target near $1.5B in enterprise value.
- A routine shareholder investigation is reviewing whether Personalis is being sold at a fair price, adding a modest background overhang.
Live Update At 12:32:29 EDT: On Thursday, September 17, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 14.41%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Tempus AI (TEM) has been trading like a momentum name with real fundamentals behind it. On 2026/08/24, TEM closed at $66.17. Less than a month later, on 2026/09/17, it finished at $80.05. That is a sharp move higher, and it followed the company’s strong Q2 2026 print and M&A headlines.
Q2 revenue for Tempus AI came in at $382.5M, up 22% year over year. For a scaled diagnostics and data‑licensing platform, that kind of growth signals demand is real, not hype. Gross margin near 73.5% shows the core Tempus AI model throws off solid unit economics, even though EBIT margin and profit margins are still negative on a trailing basis.
The key shift is at the bottom line. TEM generated positive net income of about $5.6M and positive EBITDA of roughly $45M in the quarter, a big swing from prior losses. Cash remains sizable at around $599.6M, with a current ratio of 3.3, giving Tempus AI cushion as it pushes expansion and the Personalis deal.
More Breaking News
- JAGX Stock Whipsaws As Rare-Disease Catalysts Meet Cash Strain
- DNN Stock Slides As Traders Weigh Cash Strength Against Losses
- WHLR Stock Rockets On Reverse Split And Heavy Trading
- Everpure Stock Jumps As S&P 500 Inclusion Fuels Buying
On the chart, TEM’s intraday action on 2026/09/17 shows heavy morning range from the low $70s to above $80, then a steady hold of those gains. For short‑term traders, that combination of earnings momentum, liquidity, and strong closes has been a clear catalyst for breakout‑style trading.
Why Traders Are Watching Tempus AI Now
Traders are locked in on Tempus AI because the story hits two hot themes at once: real earnings progress and a bold AI‑driven healthcare expansion plan. Q2 2026 was the proof‑of‑concept quarter. TEM delivered 22% revenue growth to $382.5M, improved gross profit, and, most importantly, a turn to positive net income and EBITDA. When a previously money‑losing growth story flips the profit switch, Wall Street tends to re‑rate the stock.
Under the hood, Tempus AI leaned on its strengths. The company highlighted strong oncology testing volume, which is its bread‑and‑butter diagnostics engine. At the same time, the Data and Applications segment posted robust growth. That piece matters a lot. Data and software‑style revenue usually carries higher margins, and for TEM it validates the “context is the asset” thesis around its multimodal clinical and molecular datasets.
Tempus AI is not just running lab tests; it is building an AI‑ready data stack for drug discovery and development. That framing helps explain why traders are willing to pay a rich price‑to‑sales multiple today. They are trading on where the model can go if data‑licensing and AI applications scale.
Layered on top of that, Tempus AI dropped a major M&A headline. The company plans to acquire Personalis for $16.25 per share, in a deal valuing the target around $1.5B in enterprise value. For TEM, this is a swing at expanding its precision‑medicine footprint and dataset breadth. Bigger data, more clinical context, stronger AI training loops — that is the strategic pitch.
There is some noise: a shareholder investigation on the Personalis side is checking whether the sale price is fair. These reviews are common around takeovers, but short‑term traders in Tempus AI still need to watch for any delay or renegotiation headlines that could jolt the tape.
Conclusion
Tempus AI sits at an interesting crossroads for active traders. On one side, the fundamentals are finally lining up. Q2 2026 showed TEM can grow fast, with 22% revenue expansion, while also crossing into positive net income and EBITDA. High gross margins and a strong cash position give Tempus AI room to keep pushing its precision‑medicine and data‑licensing strategy without immediately tapping markets for fresh capital.
On the other side, the story is getting bigger — and more complex. The planned $1.5B Personalis acquisition is a major bet that more data and deeper genomic capabilities will reinforce the Tempus AI platform. If integration goes smoothly and the combined datasets feed into new AI‑driven drug discovery and diagnostics products, traders may view the deal as a turning point. If execution stumbles, leverage and deal fatigue can become overhangs. The shareholder fairness investigation around Personalis is standard, but it remains part of the risk backdrop for TEM.
For active traders, this is where discipline comes in. Tempus AI has momentum, volatility, and a clear narrative — ideal conditions for short‑term setups, but also for painful reversals when sentiment shifts. As Tim Sykes likes to say, “the market doesn’t care about your opinion, only your plan and how fast you cut losses.” And as Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.”. With TEM, understand the earnings, respect the deal risk, watch the key levels on the chart, and trade the price action — not the hype.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.